Shire strides ahead with strong annual and 4th-qtr results

16 February 2017
2019_biotech_test_vial_discovery_big

In its fourth quarter and full year financial results statement, Ireland-incorporated Shire (LSE: SHP) posted stronger-than-expected sales and profits today, resulting in a 2.5% jump in the company’s share price.

The company missed analysts’ expectations in the third quarter of last year, largely due to the absorption of costs related to its $32 billion takeover of American biotech firm Baxalta.

In the fourth quarter of 2016 Shire achieved revenues of $3.8 billion, up 122% from the year earlier, following generally accepted accounting principles (GAAP). Net income was $457 million, an increase of 63%. Earnings per share (EPS) stood at $1.51.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology